Pfizer Earnings Miss, Revenue Beats In Q4

This post was originally published on this site

https://i-invdn-com.akamaized.net/news/pfizer_M_1440049959.jpg

Investing.com – Pfizer announced fourth quarter that missed analysts’ expectations on Tuesday and revenue that topped forecasts.

The company said adjusted diluted earnings per share fell 13% on the year in the fourth quarter to 55c, on a 9% drop in revenue to $12.69 billion.

Analysts polled by Investing.com anticipated EPS of $0.58 on revenue of $12.61 billion.

Analysts are expecting EPS of $0.72 and revenue of $11.7B in the upcoming quarter.

Pfizer stock’s are up 2.5% for the year to date , still down 9.87% from its 52 week high of $44.56 set on July 3, 2019.

Pfizer follows other major Healthcare sector earnings this month

On January 22, J&J reported fourth quarter EPS of $1.88 on revenue of $20.75B, compared with a forecasts for EPS of $1.87 on revenue of $20.8B.

Abbott Labs earnings matched analysts’ expectations on January 22, with fourth quarter EPS of $0.95 on revenue of $8.31B. Investing.com analysts anticipated EPS of $0.95 on revenue of $8,263M

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.